Enanta aims to raise $50M as it advances RSV therapy; Hinge, Kyorin make a dealnews2025-10-01T14:17:17+00:00October 1st, 2025|Endpoints News|
Barinthus’ reverse merger with private biotech; Sutro to lay off 33% of employeesnews2025-09-30T14:36:27+00:00September 30th, 2025|Endpoints News|
IO Biotech to run another study for cancer vaccine; Boehringer ends mid-stage IPF trial news2025-09-29T14:24:07+00:00September 29th, 2025|Endpoints News|
Lilly’s Kisunla gets EU approval; Sanofi expands insulin discount programnews2025-09-26T14:52:47+00:00September 26th, 2025|Endpoints News|
Kardigan gets the rights to a MyoKardia drug; Lilly stops Phase 2 trial for muscle-sparing candidatenews2025-09-25T15:29:36+00:00September 25th, 2025|Endpoints News|
Hengrui, Glenmark ink ADC deal; Rome Therapeutics to seek ‘strategic options’news2025-09-24T14:30:23+00:00September 24th, 2025|Endpoints News|
Invivo aims to raise €100M for fourth fund; SEED Therapeutics gets $30Mnews2025-09-23T14:25:11+00:00September 23rd, 2025|Endpoints News|
FDA pushes back decision on Sanofi’s BTK inhibitor; Roche makes a deal with Starpharmanews2025-09-22T15:15:10+00:00September 22nd, 2025|Endpoints News|
Nektar’s stock rallies on eczema data; Novo to lay off 263 workers in NJnews2025-09-18T14:47:51+00:00September 18th, 2025|Endpoints News|
X4 Pharmaceuticals restructures; Cytokinetics targets $650M raisenews2025-09-17T14:42:49+00:00September 17th, 2025|Endpoints News|
